Stoke, Biogen and Dravet syndrome
Existing treatments for Dravet include Jazz Pharmaceuticals’ Epidiolex and UCB’s Fintepla, but none of the approved products address the underlying genetic cause of the syndrome. Similarly ...
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...
(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics, Inc. (STOK) Tuesday announced partnership to develop and sell zorevunersen, Stoke's drug candidate for the treatment of Dravet syndrome ...
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...
Study: Neonatal but not Juvenile Gene Therapy Reduces Seizures and Prolongs Lifespan in SCN1B-Dravet Syndrome Mice. Image Credit: Natali _ Mis/Shutterstock.com Developmental and epileptic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback